Jim Cramer: The Allergan-Pfizer Deal Is Absolutely Dead

Jim Cramer says the merger between Pfizer and Allergan isn't going anywhere, as lawmakers try to limit corporate inversions.
Author:
Publish date:

TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer said the merger between Pfizer (PFE) - Get Report and Allergan (ACT) - Get Report isn't going anywhere, as lawmakers try to limit corporate inversions. 'We have a position for Action Alerts PLUS, and we have been waiting for it to come down,' Cramer said. 'We didn't think it would come down this much.' He thinks Allergan is a 'screaming buy' below $220 a share.

At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.